Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker.
T-cell prolymphocytic leukemia (T-PLL) is a rare post-thymic T-cell neoplasm with aggressive clinical course and short overall survival. So far, due to the rareness of this disease, genetic data are available only from individual cases or small cohorts. In our study, we aimed at performing a comprehensive cytogenetic and molecular genetic characterization of T-PLL comprising the largest cohort of patients with T-PLL analyzed so far, including correlations between the respective markers and their impact on prognosis. Genetic abnormalities were found in all 51 cases with T-PLL, most frequently involving the TCRA/D locus (86%). Deletions were detected for ATM (69%) and TP53 (31%), whereas i(8)(q10) was observed in 61% of cases. Mutations in ATM, TP53, JAK1, and JAK3 were detected in 73, 14, 6, and 21% of patients, respectively. Additionally, BCOR mutations were observed for the first time in a lymphoid malignancy (8%). Two distinct genetic subgroups of T-PLL were identified: A large subset (86% of patients) showed abnormalities involving the TCRA/D locus activating the proto-oncogenes TCL1 or MTCP1, while the second group was characterized by a high frequency of TP53 mutations (4/7 cases). Further, analyses of overall survival identified JAK3 mutations as important prognostic marker, showing a significant negative impact.
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, 81377, Germany.
Anna
A
Stengel
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, 81377, Germany.
Wolfgang
W
Kern
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, 81377, Germany.
Melanie
M
Zenger
MLL2 S.R.O., KCD4, Kolbenova 609/40, 190 00 Praha 9, Czech Republic.
Karolína
K
Perglerová
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, 81377, Germany.
Susanne
S
Schnittger
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, 81377, Germany.
Torsten
T
Haferlach
MLL Munich Leukemia Laboratory, Max-Lebsche-Platz 31, Munich, 81377, Germany.
Claudia
C
Haferlach
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D005260:Female; D014644:Genetic Variation; D006801:Humans; D053616:Janus Kinase 3 / Q000235:genetics*; D015461:Leukemia, Prolymphocytic, T-Cell / Q000235:genetics* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D017422:Sequence Analysis, DNA; D016019:Survival Analysis
C507933:JAK3 protein, human; D053616:Janus Kinase 3